Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders

  • End date
    Feb 7, 2023
  • participants needed
  • sponsor
    Memorial Sloan Kettering Cancer Center
Updated on 7 May 2021


This study will evaluate whether a geriatric assessment can lead to better treatment outcomes in older patients (age 60+) with myelodysplastic syndromes, myeloproliferative neoplasms, or related blood disorders who are going to receive chemotherapy or another treatment to prepare the body for an allogeneic hematopoietic stem cell transplant (allo-HCT). The geriatric assessment includes looking at patients' cognitive function (thinking processes), physical function, mobility (ability to move the body), mood, nutrition, and current medications to help decide the type of treatment they'll receive.

Another purpose of this study is to see whether use of the geriatric assessment improves participants' quality of life. We will evaluate participants' quality of life through questionnaires.


This is a prospective, phase II study evaluating the efficacy of a risk-adapted, personalized allo-HCT strategy based on geriatric vulnerabilities identified by pre-transplant GA. The less vulnerable/fit older patients are recommended to receive MA conditioning and the more vulnerable older patients are recommended to receive RIC/NMA conditioning.

  1. HCT-CI/Age 4 AND no IADL impairment (less vulnerable/fit) -> MA regimen
  2. HCT-CI/Age >4 AND/OR any IADL impairment (more vulnerable) -> RIC/NMA regimen
    • Chemotherapies: busulfan, fludarabine, melphalan, cyclophosphamide, thiotepa, clofarabine
    • Radiation therapy: total body irradiation (TBI)
    • Other therapy: anti-thymocyte globulin (ATG)

Condition Bone marrow disorder, Chronic myelomonocytic leukemia, Juvenile Myelomonocytic Leukemia, Preleukemia, Philadelphia-Negative Myelogenous Leukemia, MYELOPROLIFERATIVE DISORDER, MYELODYSPLASTIC SYNDROME, Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms, myelodysplastic syndromes, myeloproliferative neoplasm, myeloproliferative disorders, atypical chronic myeloid leukemia, myelodysplastic syndrome (mds), chronic myelomonocytic leukaemia, cmml, Myelodysplastic/Myeloproliferative Overlapping Syndrome, Myelodysplastic/Myeloproliferative Overlapping Syndrome, Myelodysplastic/Myeloproliferative Overlapping Syndrome, Myelodysplastic/Myeloproliferative Overlapping Syndrome
Treatment Conditioning regimen, Geriatric assessment (GA) pre-transplant, Allogeneic CD34+ selected stem cells
Clinical Study IdentifierNCT04761770
SponsorMemorial Sloan Kettering Cancer Center
Last Modified on7 May 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 60 yrs?
Gender: Male or Female
Do you have any of these conditions: myelodysplastic syndromes or Chronic myelomonocytic leukemia or MYELODYSPLASTIC SYNDROME or Myelodysplastic Syndromes (MDS) or atypical chronic myeloi...?
Do you have any of these conditions: Myeloproliferative Neoplasms or chronic myelomonocytic leukaemia or Juvenile Myelomonocytic Leukemia or myelodysplastic syndrome (mds) or Myelodysplas...?
Do you have any of these conditions: cmml or myeloproliferative neoplasm or Myelodysplastic/Myeloproliferative Overlapping Syndrome or myelodysplastic syndromes or chronic myelomonocytic ...?
Do you have any of these conditions: myeloproliferative neoplasm or Philadelphia-Negative Myelogenous Leukemia or atypical chronic myeloid leukemia or Bone marrow disorder or MYELODYSPLAS...?
are 60 years or older
have pathologically confirmed myelodysplastic syndrome, myeloproliferative neoplasms, or related blood disorders including chronic myelomonocytic leukemia, atypical chronic myeloid leukemia, and myelodysplastic/myeloproliferative overlapping syndrome
have <10% blasts in bone marrow prior to transplant
have a matched related or unrelated donor, mismatched unrelated donor, or haploidentical donor
Meet institutional standard criteria for allogeneic transplantation as determined by the primary transplant physician

Exclusion Criteria

Prior hematopoietic cell transplantation
Cord blood donors
Persons with active, refractory disease defined by 10% blasts in bone marrow prior to transplant
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note